Jacobs Levy Equity Management
CCCC icon

Jacobs Levy Equity Management’s C4 Therapeutics CCCC Stock Holding History

Jacobs Levy Equity Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$696K Buy
+264,620
New +$623K ﹤0.01% 769
2025
Q4 		– Sell
-503,145
Closed -$1.12M – 940
2025
Q3 		$1.12M Buy
503,145
+61,410
+14% +$147K ﹤0.01% 695
2025
Q2 		$632K Sell
441,735
-255,918
-37% -$372K ﹤0.01% 840
2025
Q1 		$1.12M Buy
+697,653
New +$2.08M ﹤0.01% 791
2024
Q1 		– Sell
-100,370
Closed -$567K – 948
2023
Q4 		$567K Sell
100,370
-764,111
-88% -$1.74M ﹤0.01% 810
2023
Q3 		$1.61M Buy
864,481
+135,540
+19% +$413K 0.01% 599
2023
Q2 		$2M Buy
728,941
+5,240
+0.7% +$16.8K 0.01% 565
2023
Q1 		$2.27M Sell
723,701
-4,970
-0.7% -$29.3K 0.01% 549
2022
Q4 		$4.3M Sell
728,671
-10,322
-1% -$85.6K 0.03% 423
2022
Q3 		$6.48M Buy
738,993
+206,573
+39% +$2.14M 0.05% 337
2022
Q2 		$4.01M Buy
+532,420
New +$4.68M 0.03% 458
2021
Q3 		– Sell
-23,413
Closed -$886K – 1043
2021
Q2 		$886K Buy
+23,413
New +$839K 0.01% 762

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jacobs Levy Equity Management's CCCC Position: Q1 2026 in Review

Jacobs Levy Equity Management opened a new position in C4 Therapeutics (CCCC) in Q1 2026: 264,620 shares worth $696K. The stake represents ﹤0.01% of the portfolio and ranks #769 among its holdings. This is a return to the name: Jacobs Levy Equity Management previously reported a position in CCCC as recently as Q3 2025.

Jacobs Levy Equity Management first reported a position in CCCC in Q2 2021 and has held it in 12 quarters since. The position peaked at $6.48M in Q3 2022. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Jacobs Levy Equity Management held 264,620 shares of C4 Therapeutics worth $696K as of Q1 2026.
  • C4 Therapeutics was a new Jacobs Levy Equity Management position in Q1 2026.
  • C4 Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #769 holding.
  • Jacobs Levy Equity Management first reported a position in C4 Therapeutics in Q2 2021 and has held it in 12 quarters since.
  • Jacobs Levy Equity Management's C4 Therapeutics position peaked at $6.48M in Q3 2022.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.